Filana Therapeutics

Update in progress

FLNA (NasdaqCM)

Filana Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for neurodegenerative diseases. Its lead therapy is simufilam, a small-molecule drug in Phase 3 trials for Alzheimer's disease, and its investigational diagnostic program SavaDx aims to detect Alzheimer's from a blood sample. The firm was formerly Cassava Sciences, renamed Filana Therapeutics in March 2026. It was founded in 1998 and is based in Austin, Texas.